BIOCON.NSE News
Who is Claire Mazumdar? Meet Kiran Mazumdar-Shaw’s chosen successor at Biocon
Biocon Founder and Executive Chairperson Kiran Mazumdar-Shaw has chosen her niece Claire Mazumdar to succeed her as the biotech entrepreneur laid out a succession plan for India’s leading biotech firm. Mazumdar-Shaw (73), who has no children, in a post on X, confirmed reports about the succession planning in Biocon and that she has choosen niece […]
cityfalcon.com
Who is Claire Mazumdar? Meet Kiran Mazumdar-Shaw’s chosen successor at Biocon
Biocon Founder and Executive Chairperson Kiran Mazumdar-Shaw has chosen her niece Claire Mazumdar to succeed her as the biotech entrepreneur laid out a succession plan for India’s leading biotech firm. Mazumdar-Shaw (73), who has no children, in a post on X, confirmed reports about the succession planning in Biocon and that she has choosen niece […]
cityfalcon.com
India Business News: Kiran Mazumdar-Shaw, founder and chairperson of Biocon, has found her successor within the family. She outlined a gradual succession plan, naming her .
cityfalcon.com
Kiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who built the company from a garage into a global biotech leader, Kiran is ensuring continuity by handing over to a science-driven leader while remaining at the helm during the transition.
cityfalcon.com
Biocon founder and chairperson Kiran Mazumdar-Shaw has proposed her niece as her successor. In a formal succession plan for the company, the 73-year-old matriarch has put forward the name of Claire Mazumdar, currently the chief executive officer of Bicara Therapeutics
cityfalcon.com
Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals.
cityfalcon.com
Indian conglomerate Reliance Industries is expected to post its Q2 earnings today.
The new U.S. duty has already triggered a slide in major Asian pharma names, raising concerns about how Indian peers will react in the coming weeks.
The analyst noted that Syngene, Piramal Pharma, and Zydus Lifesciences may be better positioned, as their contract manufacturing models and biologics portfolios are less susceptible to the tariff impact.
Stocks such as Elgi Equipment, Supriya Life and Bajaj Consumer are on the breakout radar with upside potential, say analysts.
The broader markets are expected to open on a positive note after the US Federal Reserve slashed the benchmark interest rate by 25 basis points.